KIF22 and Familial prostate cancer: Studies have revealed that KIF22 was overexpressed in many cancers, such as lung cancer (Pike et al. 2018), gastric cancer (Yu et al. 2020), breast cancer (Yu et al. 2014), and prostate cancer (Zhang et al. 2018), and was associated with poor prognosis.